Science Daily -
15 Jan 2019 20:29
Researchers have successfully used CRISPR/Cas9 to limit the impact of schistosomiasis and liver fluke infection, which affects more than a quarter of a billion people in Southeast Asia, sub-Saharan Africa, and Latin America.
Share this Article